行情

MLND

MLND

Millendo Therapeutics Inc
NASDAQ

实时行情|Nasdaq Last Sale

6.07
-0.27
-4.26%
盘后: 6.07 0 0.00% 16:00 12/11 EST
开盘
6.28
昨收
6.34
最高
6.38
最低
6.01
成交量
5.14万
成交额
--
52周最高
17.34
52周最低
4.560
市值
1.07亿
市盈率(TTM)
-0.5395
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

MLND 新闻

  • CLVS, AUPH, ESTC and HOV among midday movers
  • Seeking Alpha - Article.6天前
  • SAGE, ESTC among premarket losers
  • Seeking Alpha - Article.6天前
  • The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission
  • Benzinga.6天前
  • The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission
  • Benzinga.6天前

更多

所属板块

生物技术和医学研究
-0.34%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

MLND 简况

Millendo Therapeutics, Inc., formerly OvaScience, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing novel treatments for orphan endocrine diseases. The Company is focused on advancing two product candidates to treat three indications. Its advanced product candidate, livoletide (AZP-531), is a potential treatment for Prader-Willi syndrome (PWS), which is a rare and complex genetic endocrine disease characterized by hyperphagia, or insatiable hunger. It is also developing nevanimibe (ATR-101) with a primary focus on treating patients with classic congenital adrenal hyperplasia (CAH), which is a rare, monogenic adrenal disease that requires lifelong treatment with exogenous cortisol.
展开

Webull提供Millendo Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。